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We have previously found that retinoic acid stimulates the expression of protein kinase C␣ (PKC) in B16
mouse melanoma cells. Because it has been reported
that PKC can phosphorylate retinoic acid receptor
(RAR) and alter its function, we determined whether
changes in the level and/or activity of PKC could affect
the expression or function of the RAR in B16 melanoma.
Using in vivo phosphorylation and band shift techniques, we could not demonstrate that altering PKC
activity and/or protein level changed the in vivo phosphorylation of RAR␣. However activation of PKC resulted in increased RAR␣ protein. Increased receptor
protein correlated with a phorbol dibutyrate-stimulated
increase in receptor activation function-2 (AF-2)dependent transcriptional activity. Use of enzyme inhibitors and dominant-negative PKCs indicated that enzyme activity was required for elevation in the RAR␣.
The PKC-mediated increase in RAR␣ was due to a 2.5fold increase in the half-life of this protein. In contrast,
the down-regulation of PKC diminished RAR␣ protein
half-life and markedly inhibited AF-2-dependent transcriptional activity. The down-regulation of PKC also
inhibited the binding of RAR to a retinoic acid response
element and the retinoic acid induction of RAR␤ expression. These findings suggest that PKC can influence retinoic acid signaling by altering the stability of RAR protein without directly phosphorylating this receptor.

All trans-retinoic acid (RA)1 is the major biologically active
form of vitamin A. This vitamin is important for normal growth
and development, especially during embryogenesis where a
three-dimensional gradient of RA determines pattern formation (1). It is also an important regulator of reproduction (2),
differentiation (3), and apoptosis (4). Additionally, RA has been
found to inhibit the growth of malignant cells (5, 6) and/or to
induce reversion from the malignant to the normal phenotype
(7). Most, if not all, of all these effects are mediated though
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retinoid nuclear receptors. There are two families of retinoid
nuclear receptors: RARs and RXRs. Each family of nuclear
retinoic acid receptors consists of ␣, ␤, and ␥ subtypes (8 –10).
These nuclear receptors are ligand-dependent transcriptional
regulators, with RXR being activated by 9-cis-RA, whereas
RAR are activated by either all-trans-RA or 9-cis-RA (11–13).
RXR can form homodimers with a number of other type II
nuclear receptors, including RAR (14, 15). In contrast, RAR
only forms heterodimers with RXR (16). Following ligand binding, RXR䡠RAR heterodimers bind to the promoter of target
genes and stimulate their transcription (17). In B16 mouse
melanoma cells RAR␣ and RAR ␥ are constitutively expressed,
whereas RAR␣ expression can be induced by incubation of cells
with RA (18).
Nuclear retinoic acid receptors are phosphoproteins. RAR␣ is
phosphorylated in vivo by cyclic AMP-dependent protein kinase (PKA) (19) and cyclin-activating kinase (CAK) (20). Phosphorylation of RAR␣ by PKA in F9 cells is required for RAinduced parietal endoderm differentiation (21). In contrast,
proline-directed phosphorylation sites (such as those phosphorylated by CAK) in RAR␥ were required for RA induction of
primitive endoderm differentiation (22). The PKA phosphorylation site in RAR␥ was dispensable for this biological activity of
RA (21).
Protein kinase C (PKC) is a serine/threonine protein kinase
and plays a role in the regulation of growth, differentiation,
and other cellular functions (23). The PKC family includes at
least 11 different enzymes that are classified into three families based on requirement for phospholipids, diacylglycerol, or
Ca2⫹ for their activation (24, 25). Following activation, PKC is
translocated to different cellular compartments where it phosphorylates substrate proteins. In addition, PKC has been
shown to transverse the nuclear membrane and phosphorylate
targets in the nucleus (26). The transcription complex activating protein 1 is activated by PKC (27), which provides a means
for PKC to influence gene expression.
It has been proposed that there is an interaction between
PKC and retinoic acid receptors. PKC has been shown to phosphorylate RAR in vitro (28, 29). On the other hand, one group
has reported that RA binds to PKC in a specific manner and
inactivates its enzymatic activity (30). We have previously reported that treatment of B16 melanoma cells with RA increases
the amount of PKC␣ mRNA and protein (31). In light of the
purported interaction between PKC and RAR, we investigated
whether the increased amount of PKC␣ in B16 cells might
phosphorylate the RAR and alter its function. We found, in B16
mouse melanoma cells, that RAR␣ is not a target for PKCdirected phosphorylation. However, we discovered that activation of PKC in these cells resulted in an increase in RAR␣
protein. The increase in RAR␣ was due to an increase in the
half-life of this protein, which correlated with an increase in
AF-2 activity. In contrast, down-regulation of PKC through
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prolonged phorbol dibutyrate (PDB) treatment led to a large
decrease in AF-2 activity, which cannot be totally accounted for
by diminished RAR stability. Our studies suggest that there
exists a significant cross-talk between the PKC and RAR signal
transduction pathways.
EXPERIMENTAL PROCEDURES

Cell Culture—B16 mouse melanoma cells were grown in DMEM
(Invitrogen, Rockville, MD) supplemented with 10% bovine calf serum
(HyClone Laboratories, Logan, UT) at 37 °C, in a 5% CO2/95% air,
humidified atmosphere. Cells were treated for the periods described in
each experiment with 10 M phorbol 12,13-dibutyrate (PDB) (Sigma
Chemical Co., St. Louis, MO) or 10 M all-trans-RA (Fluka Chemical
Corp., Ronkonkoma, NY). All manipulations involving RA were conducted
under subdued lighting or yellow light to prevent photo-oxidation.
Cloning of mRAR␣ into a Histidine-tagged Expression Vector—A
mRAR␣ cDNA fragment encoding the complete open reading frame,
except for the last three C-terminal amino acids was produced by PCR
using the following primers: 5⬘-GGACTGGCCAGCAACAGC-3⬘ (upstream primer) and 5⬘-GGCCGGGCTGCTTCTGTT-3⬘ (downstream
primer) using the Advantage cDNA PCR kit (CLONTECH, Palo Alto,
CA). The template for this reaction was mRAR␣ in pSG5 that was
kindly provided by Dr. Pierre Chambon (Institut de Genetique et de
Biologie Moleculaire et Celluaire, CNRS/INSERM, Strasbourg,
France). PCR was conducted by incubating at 94 °C for 1 min followed
by 20 cycles at 94 °C for 30 s and 68 °C for 3 min, and ending with
incubation at 68 °C for 3 min. Following authentication of the PCR
product by DNA sequencing, it was cloned into the pcDNA3.1/V5/
His-TOPO plasmid (Invitrogen, Carlsbad, CA) producing RAR␣-His. In
vitro transcription/translation of this construct resulted in a protein
that was about 5 kDa larger than wild type RAR␣. Histidine-tagged
RAR␣ had the same ligand binding and DNA binding properties as wild
type RAR␣ (data not shown).
Kinase-inactive PKC␣ Constructs—Two plasmids expressing enzymatically inactive PKC␣ were gifts from Dr. S. Ohno, Yokohama City
University School of Medicine, Japan. One of these constructs (PKC␣Kn-SM) has a single K368R mutation in the ATP binding region. The
other construct (PKC␣-Kn-TM) has the same K368R mutation in addition to two amino acid mutations (R22A and A25E) in the pseudosubstrate region. Both PKC␣ mutants expressed from these constructs
have no kinase activity. PKC␣-Kn-SM is thought to be in a “closed”
conformation, because it lacks the ability to autophosphorylate to
achieve the mature conformation. PKC-Kn-TM, in contrast, is thought
to have an “open” conformation due to the mutation in the pseudosubstrate region. B16 clones expressing these mutant PKC␣ proteins
were used to examine the requirement of PKC enzyme activity for its
effect on RAR stability.
Transient Transfections—RAR␣-His, pSG5 RAR␣, ␤, or ␥ (gifts from
Dr. Chambon), RARE-tk-luciferase (gift from Dr. Ozato, Laboratory of
Molecular Growth Regulation, National Institutes of Health, Bethesda,
MD), and pSV-␤-gal plasmids were transiently transfected into B16
cells using LipofectAMINE Plus (Invitrogen, Rockville, MD) according
to the manufacturer’s recommended protocol. For reporter gene assays,
transfected cells were treated with PDB and/or RA for the indicated
times, and 48 h after transfection cells were harvested and assayed
for luciferase or ␤-galactosidase activity using kits from Promega
(Madison, WI).
Western Blotting—Cells were lysed in buffer A (10 mM Tris-HCl, pH
7.6, 1 mM EDTA, 10% glycerol, 1 g/ml leupeptin, 1 g/ml pepstatin, 2
g/ml aprotinin, and 3.28 g/ml PMSF) by three consecutive 10-s sonications with a Tekmar sonic disrupter at power setting 60. Proteins
were separated by SDS-PAGE (5% stacking gel; 10% separating gel)
and transferred to nitrocellulose (Micron Separation, Inc., Westborough,
MA) using a semi-dry blotting apparatus (Bio-Rad, Hercules, CA). The
membranes were incubated with 10% nonfat dry milk overnight at
room temperature. The membrane was then washed 3⫻ with TBST (10
mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 5 min each, at
room temperature and then probed with a 1:5000 dilution of anti-V5
monoclonal antibody (Invitrogen, Carlsbad, CA) for 1 h at room temperature. Subsequently, the membrane was washed as described above
and further incubated with horseradish peroxidase-conjugated sheep
anti-mouse IgG (Amersham Biosciences, Piscataway, NJ) at room temperature for 1 h. The membrane was washed three times with TBST
and developed using the ECL chemiluminescence kit (Amersham Biosciences). Intensity of the RAR␣-His immunoreactive bands was quantified using a Molecular Dynamics densitometer (Sunnyvale, CA).
-Phosphatase Treatment of RAR␣-His—B16 cells were transiently

transfected with the plasmid encoding the RAR␣-His protein as described above, harvested in buffer A and disrupted by sonication. 50 g
of protein extract was treated with 100 units of -phosphatase (New
England BioLabs, Beverly, MA) in 50 mM Tris-HCl, pH 7.8, 0.1 mM
EDTA, 5 mM dithiothreitol, 0.01% Brij 35, 2 mM MnCl2 in a total volume
of 20 l for different time periods at 30 °C.
In Vivo Phosphorylation of RAR␣—B16 cells were transfected with
the RAR␣-His expression vector. Twenty-four hours after transfection,
medium was changed and cells were incubated overnight in phosphatefree DMEM (Invitrogen, Carlsbad, CA). Cells were then incubated for
4 h in the same medium in the presence of 250 Ci of [32P]orthophosphate (Amersham Biosciences) and 100 M orthovanadate (Sigma
Chemical Co., St. Louis, MO). At the end of this incubation, cells were
washed and harvested in cold PBS. RAR␣ was purified by immunoprecipitation as described below and separated by SDS-PAGE on a 7.5%
gel. The gel was dried and then exposed to x-ray film for 72 h.
Immunoprecipitation and Determination of RAR␣-His Protein Halflife—B16 cells were transfected with the RAR␣-His construct as described previously. At 44 h post-transfection, media was removed and
replaced with methionine-free DMEM (Invitrogen, Rockville, MD) for
1 h. This medium was then replace with fresh methionine-free medium
to which 100 Ci/ml [35S]methionine (PerkinElmer Life Sciences,
Boston, MA) was added, and the cells were incubated for an additional
2 h. At different times of experimental treatment, medium was removed
and cells were washed with PBS and harvested in 0.9 ml of radioimmune precipitation buffer (1% Nonidet P-40, 0.5% sodium deoxycholate,
1% SDS, 100 g/ml PMSF, 30 g of aprotinin, 1 mM sodium orthovanadate in PBS). Cells were disrupted by repeated aspiration through a
21-gauge needle. The cell lysate was centrifuged at 10,000 ⫻ g for 10
min at 4 °C, and the supernatant was precleared by the addition of 1 g
of mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA) together
with 20 l of protein A-agarose (Santa Cruz Biotechnology) for 30 min
at 4 °C. The protein A-agarose was removed by centrifugation at 2500 ⫻
g for 5 min at 4 °C, 0.7 g of anti-V5 epitope antibody was then added,
and the mixture was incubated for 1 h at 4 °C. Immune complexes were
collected by the addition of 20 l of protein A-agarose for 1 h at 4 °C
followed by centrifugation at 2500 ⫻ g for 5 min at 4 °C. The immunoprecipitate was washed three times by resuspension in 1 ml of radioimmune precipitation buffer followed by centrifugation as described
previously. The pellet was resuspended in 30 l of SDS samples buffer,
and 25 l was loaded onto a 5% stacking/10% separating SDS gel for
protein separation by electrophoresis. The gel was then dried using a
Model 583 gel drier (Bio-Rad, Hercules, CA), and the RAR␣-His protein
was detected by autoradiography. The amount of RAR␣-His was determined by densitometry.
Northern Blotting—RNA was isolated by a single-step method as
described previously (32). The RNA was then fractionated on 1% agarose containing formaldehyde and transferred to Hybond N nylon membranes (Amersham Biosciences, Chicago, IL) by downward alkaline
blotting. The transferred RNA was cross-linked to the membrane by UV
light. The membrane was prehybridized for 1 h in 6⫻ SSC and 2% SDS.
32
P-Labeled cDNA probes (1 ⫻ 106 dpm/ml) were then incubated with
the membranes in fresh hybridization solution for 20 h. Blots were
washed three times for 15 min each in 1⫻ SSC plus 0.1% SDS, 0.5⫻
SSC plus 0.1% SDS, and 0.2⫻ SSC plus 0.1% SDS, respectively. The
blots were exposed to Kodak XAR film in cassettes at ⫺70 °C for 2–5
days. All the cDNA probes were labeled using the “prime-a-gene” labeling system from Promega (Madison, WI) plus 0.25 mCi of [␣-32P]dCTP.
The relative amount of the different RNA species was quantitated by
imaging the autoradiogram with a Molecular Dynamics laser densitometer, making sure that the signals were within the linear range of the
instrument. The data are expressed as the ratio of the specific mRNA to
the internal control, glyceraldehyde-3-phosphate dehydrogenase.
Electrophoretic Mobility Shift Assay—Two 33-bp DNA oligonucleotides were annealed to form a double-stranded oligonucleotide, which
contained a retinoic acid response element corresponding to that found
within the human RAR␤ gene promoter (33). This ␤RARE was labeled
with [␣-32P]dCTP (3000 Ci/mmol) by end-filling of the 5⬘-protruding
termini with the Klenow fragment of DNA polymerase I. The labeled
␤RARE was purified using a Qiagen Tip-20, precipitated with 10 mg of
glycogen carrier in ethanol:acetone (1:3, v/v) at ⫺80 °C, and resuspended in double distilled H2O.
Gel shift reactions typically contained B16 nuclear extract (25 g) or
Sf9 cell extracts from recombinant hRAR␣1 baculovirus-infected cells
(1 g), 10% (v/v) glycerol, 10⫻ reaction buffer (0.2 M HEPES, pH 7.9, 0.6
M KCl, 0.01 M Na2EDTA, 0.1 M monothioglycerol, and 0.01 M PMSF), 2.5
g of poly(dI-dC), and 2 ⫻ 104 cpm of [␣-32P]␤RARE in a 20-ml total
volume. The reactions were incubated for 20 min at 23–24 °C and
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FIG. 1. Ectopically expressed His6-RAR␣ is phosphorylated.
B16 cells were transfected with the His6-RAR␣ plasmid. At 24 h following transfection, cells were extracted and incubated with -phosphatase
as described in the text. Equal amounts of control or treated extract
proteins were separated by SDS-PAGE in a manner that allowed maximal separation of phosphorylated forms of RAR␣ (receptor protein was
allowed to migrate to the bottom of a 10% SDS gel). The His6-RAR␣ was
detected by Western blots using an antibody against the V5-epitope
found in fusion protein. The open arrows indicate the phosphorylated
species of RAR␣.
immediately resolved at 20 mA at 23 °C in a 5% non-denaturing gel
(60:1, acrylamide:bis) in 0.5⫻ TBE (0.045 M Tris borate, pH 8.0, 0.001 M
Na2EDTA). Dried gels were exposed to film between intensifying
screens at ⫺80 °C.
All experiments described under “Results” were repeated three separate times with similar qualitative results.
RESULTS

RAR␣ Ectopically Expressed in B16 Melanoma Cells Is Phosphorylated—Expression of endogenous RAR in B16 cells is very
low and below the detection limit of Western blotting/immunoprecipitation techniques. Thus, for the studies reported here,
we used recombinant histidine-tagged RAR␣ transiently transfected and expressed in B16 cells. Histidine-tagged RAR␣ protein had the same ligand binding and DNA binding properties
as wild type RAR␣ (data not shown). Expression of the recombinant RAR␣ was confirmed by Western blotting, using an
antibody directed against the histidine tag or an antibody to
the V5 epitope, which is also part of the tagged protein. Three
immunoreactive RAR␣ bands were most often observed in extracts of transfected B16 cells, corresponding to 50 –54 kDa.
When these extracts were treated with -protein phosphatase
for different periods of time, the two RAR␣ bands of higher
molecular mass collapsed into the lowest molecular mass band
(Fig. 1) indicating that the His6-RAR␣ protein is phosphorylated in B16 cells. Elsewhere, in data presented, multiple bands
of RAR␣ may not be apparent. This is due to different gel
running conditions and signal detection conditions required to
display these multiple bands.
Activation and Down-regulation of PKC Does Not Alter the
Phosphorylation of RAR␣ in B16 Mouse Melanoma Cells—We
have previously shown that incubation of B16 cells with phorbol dibutyrate for 1 or 24 h activates or down-regulates PKC␣,
respectively (34). Therefore, we used these phorbol dibutyrate
treatment times to determine whether activation/down-regulation of PKC altered the phosphorylation of RAR␣. Fig. 2A
shows that treatment of B16 cells with phorbol dibutyrate did
not change the number of the RAR␣-immunoreactive bands
(although the amount of RAR␣ protein was higher in the 1-h
phorbol dibutyrate-treated cells, see below). Also, the ratio of
the relative amount of the different bands within each treatment group was not altered. In addition, radioactive labeling of
intact cells with 32Pi-orthophosphate did not reveal any change
in the amount of incorporation of the label into His6-RAR␣ in
short or long term phorbol dibutyrate-treated cells when the
signals were corrected for amount of receptor protein (Fig. 2B).
Increase in PKC Activity Results in Higher RAR␣ Protein
Levels in B16 Cells—Even though changes in PKC activity/
expression did not alter the phosphorylation of RAR␣, an increase in PKC activity did result in a consistent 2-fold elevation
in RAR␣ protein levels (Fig. 2A). In contrast, down-regulation

FIG. 2. Effect of PKC activation or down-regulation on RAR␣
phosphorylation. B16 cells were transfected with the His6-RAR␣
plasmid. At 24 h post-transfection they were treated with 10 M phorbol
dibutyrate for 24 h (PKC down-regulation) or for 1 h (PKC activation)
prior to harvesting. His6-RAR␣ was determined by Western blotting
using the antibody against the V5 epitope (A). B16 cells transiently
transfected with the RAR␣ construct were incubated in the presence of
[32P]orthophosphate for 4 h and 10 M phorbol dibutyrate for 1 or 24 h.
RAR␣ was then isolated by immunoprecipitation and separated on 7.5%
SDS gels. The radioactive bands were detected by autoradiography, and
the relative amount of phosphorylated RAR␣ (B) was determined by
densitometry of both the autoradiogram and silver-stained gels for
estimates of total RAR␣ protein (insets). The data are presented as the
mean relative level of phosphorylation, corrected for the amount of total
RAR␣ of three separate experiments. The error bars represent the S.E.
of the three experiments.

of PKC activity did not markedly change the level of RAR␣
protein when compared with the control.
To explore this phorbol dibutyrate-induced change in RAR␣
protein in more detail, B16 cells were incubated with phorbol
dibutyrate for different periods of time and the amount of
RAR␣ protein was determined by Western blotting. A delay of
30 min was observed before a change in RAR␣ protein levels
could be detected. RAR␣ protein levels reached a maximum, of
about 3-fold over the control level, at 10 h following phorbol
dibutyrate addition (Fig. 3A). Subsequently, RAR␣ protein levels declined and reached control levels 24 h following addition
of phorbol dibutyrate. These levels remained unchanged for the
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FIG. 3. Effect of time and concentration of phorbol dibutyrate
treatment on the amount of His6-RAR␣. Cells were transfected with
the His6-RAR␣ plasmid. Transfected cells were treated with 10 M
phorbol dibutyrate for the times indicated (A) or for 1 h with the
indicated concentrations of phorbol dibutyrate (C). Cells were then
harvested, and the relative amount of His6-RAR␣ was determined by
densitometry of the Western blots. The panel in B shows the amount of
His6-RAR␣ at time points of 15 min, 30 min, and 1 h after adding 10 M
phorbol dibutyrate to the transfected cells. The data are presented as
the mean relative amounts of His6-RAR␣ ⫾ S.E. (error bars) of three
separate experiments.

remainder of the 72-h treatment period.
The change in RAR␣ protein level as a function of phorbol
dibutyrate concentration was also analyzed. A concentration of
0.1 M phorbol dibutyrate was able to increase RAR␣ protein
levels by 2-fold following a 1-h treatment (Fig. 3C). Further
increases in phorbol dibutyrate concentration up to 50 M did
not substantially increase the level of RAR␣ protein. A 50 M
concentration of phorbol dibutyrate increased the RAR␣ protein level by an additional 50%.
PKC Activity Is Required for the Increase in RAR␣ Protein
Levels in B16 Cells—We investigated whether PKC enzyme
activity was required for the observed increase in RAR␣ protein
by using both a chemical enzyme inhibitor and dominant-negative mutants of PKC␣, which lack enzymatic activity. Bisindolylmaleimide, a selective PKC enzyme inhibitor, completely
abolished the phorbol dibutyrate-induced increase in RAR␣
protein (Fig. 4A). Clones of B16 cells stably expressing two
different types of PKC␣ dominant-negative mutants were
tested for the ability of phorbol dibutyrate to increase the
amount of ectopically expressed RAR␣. Both of these clones
have markedly less PKC-specific enzyme activity than wild
type B16 cells (Table I). Short or long term phorbol dibutyrate
treatment was not able to significantly change RAR␣ protein
levels in these clones of B16 cells further demonstrating the
requirement for PKC enzyme activity to increase the amount of
RAR␣ protein (Fig. 4B).
PKC Regulates Stability of the RAR␣ Protein in B16 Cells—
The PKC enzyme-dependent increase in RAR␣ protein could be
the result of either increased mRNA or increased stability of
the protein. Because we observed the increase in RAR␣ protein
within 1 h of addition of PDB to the cells, we considered an
effect at the RNA level unlikely, thus we examined the effect of
PKC activation on the stability of RAR␣ protein. The half-life of
ectopically expressed RAR␣ in B16 cells was determined to be
4 h. When B16 cells were treated with PDB for 1 h, the RAR␣
protein half-life increased to somewhat greater than 8 h (Fig.
5). In contrast, when PKC was down-regulated by a 24-h treatment with phorbol dibutyrate, the half-life of RAR␣ decreased
slightly to ⬃3 h (Fig. 5).
Altering PKC Activity Changes the Transcriptional Activation Function of the RAR—To further study the effect of PKC
on RARs, RAR-dependent transcriptional activity was measured in an RARE reporter assay using thymidine kinase promoter/luciferase reporter plasmid. In response to PKC activation RAR-dependent transcriptional activity was increased
⬃2.8-fold when compared with the control (untreated) cells. On
the other hand, down-regulation of PKC resulted in a 2-fold
decrease in the transcriptional activity (Fig. 6A). Similar effects were observed with ectopically expressed RARs (Fig. 6B).
One-hour PDB treatment resulted in an increase in RA-stimulated reporter gene activity in all of the RARs. In contrast, the
down-regulation of PKC resulted in a large reduction of RAstimulated reporter gene activity in all of the ectopically expressed RARs.
Lower RAR-dependent Transcriptional Activity Is a Result of
the Less RAR Being Bound to the DNA—A gel shift assay was
conducted using nuclear extracts from the cells treated with
phorbol dibutyrate for 1 and 24 h. The cells were also treated
with 10 M RA for 24 h. The DNA䡠protein complex contains
RARs, because it was possible to supershift the complex using
the RAR antibody. Pre-treatment of the cells with RA increased
the amount of the shifted complex (lane 3, Fig. 7). When nuclear extracts from B16 cells treated for 24 h with phorbol
dibutyrate were used in gel shift assays, a decrease in the
amount of the shifted complex was observed (lane 5 versus lane
2, Fig. 7). A small increase in the amount of RAR bound to DNA
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TABLE I
PKC enzyme activity in wild type and PKC␣ mutant-expressing
B16 clones
Cells were lyzed via sonication on ice with 20 mM Tris-HCl, pH 7.5, 2
mM EDTA, 1 mM dithiothreitol, 5% Triton X-100, 0.5 mM PMSF, and 10
g/ml aprotinin. The cell lyzate was centrifuged at 12,000 ⫻ g for 15
min. The supernatant was loaded onto a DEAE-cellulose anion exchange column (Cellex-D, Bio-Rad), previously equilibrated with column buffer (20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 1 mM
dithiothreitol). The column was eluted with several column volumes of
column buffer containing 100 mM NaCl. Protein in the eluate was
concentrated in a Centricon-30 microconcentrator (Amicon). Protein
concentrations were then determine by the Bradford method, and samples were diluted to equal protein amounts prior to assay with the PKC
enzyme assay kit from Amersham Biosciences. This system uses synthetic, PKC-specific substrate peptides, which become phosphorylated
with the radiolabeled phosphate group from [␥-32P]ATP. PKC-specific
enzyme activity was determined by activity in the absence and presence
of a phosphollipid, calcium/phorbol dibutyrate mixture. Radiolabeled
peptide was separated from unincorporated [32P]ATP by use of high
affinity blotting paper. Enzyme activity was calculated as pmol of 32P
incorporated into the peptide/min/mg of protein. KR 23 is a G418resistant clone derived from transfection of B16 cells with a plasmid
encoding PKC␣ with a mutation in the ATP-binding site. RE 2.1 is a
G418-resistant clone derived from transfection of B16 cells with a
plasmid encoding PKC␣ with mutation in both the pseudo-substrate
region and in the ATP-binding site.
Cell type

Enzyme activity
pmol of

B16 wild type cells
Clone KR 23
Clone RE 2.1

FIG. 4. PKC enzyme activity is required for phorbol dibutyrate
to increase the amount of His6-RAR␣ protein. A, transfected cells
were treated with 10 M phorbol dibutyrate alone for 1 h or with 10 M
phorbol dibutyrate plus 2.5 M bisindolylmaleimide (PKC enzyme inhibitor) for 1 h. Relative amounts of His6-RAR␣ were detected on
Western blots using the V5 epitope antibody (the inset is from a representative experiment). The data are expressed as the mean of the
relative amount of RAR␣ (normalized for the amount of glyceraldehyde3-phosphate dehydrogenase) ⫾ S.E. (error bars) from three separate
experiments. B, B16 clones KR23 (Lys to Arg mutation at amino acid
368 within the ATP-binding domain) and RE21 (Arg to Ala at amino
acid 22; Ala to Glu at amino acid 25 within the pseudosubstrate region;
and Lys to Arg mutation at amino acid 368 in the ATP-binding domain)
were transfected with the His6-RAR␣ plasmid. 24 h post-transfection
they were treated with phorbol dibutyrate as indicated. The relative
amount of His6-RAR␣ was detected by Western blots using the V5
epitope antibody (inset from a representative experiment). The data are
expressed as the mean of the relative amount of RAR␣ (normalized for
the amount of glyceraldehyde-3-phosphate dehydrogenase) ⫾ S.E.
(error bars) from three separate experiments.

was observed with nuclear extracts from cells in which PKC
activity was elevated (lane 4, Fig. 7).
PKC Down-regulation Inhibits the Retinoic Acid Induction of
RAR␣ mRNA in the B16 Mouse Melanoma Cells—RAR␣ is not
expressed under normal conditions in B16 mouse melanoma
cells. However, it contains a retinoic acid response element
(RARE), and therefore its expression can be induced by incubation with retinoic acid. Treatment of B16 cells with 10 M RA
for 4 h results in a 20- to 25-fold induction in RAR␣ mRNA (18).
When PKC activity in B16 cells was manipulated by short and
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FIG. 5. Effect of PKC activation/down-regulation on the halflife of His6-RAR␣ protein. At 44 h post-transfection cells were pulsed
with 100 Ci of [35S]methionine for 2 h. The cells were then incubated
for the indicated times in non-radioactive medium. At each time point,
cells were lysed and the radiolabeled His6-RAR␣ was immunoprecipitated with antibody to V5 epitope followed by capture of the immune
complexes on protein A-agarose beads. The immune complexes were then
separated by SDS-PAGE, and the amount of His6-RAR␣ was determined
by densitometry of the autoradiogram. Cells were treated with 10 M
phorbol dibutyrate during the last hour of the pulse period or treated with
10 M phorbol dibutyrate for 24 h prior to the pulse period. The data are
plotted as the percentage of the mean radioactive signal from three
separate experiments ⫾ S.E. (error bars) for His6-RAR␣ measured at the
time cells were placed into to non-radioactive medium.

long term phorbol ester treatment, it was observed that long
term treatment, which down-regulates PKC activity, inhibited
the induction of RAR␣ mRNA by 80% (Fig. 8). Short term
treatment of cells with phorbol dibutyrate did not change the
amount of RAR␤ mRNA induced by retinoic acid.
DISCUSSION

We have previously found that treatment of B16 mouse melanoma cells with retinoic acid induces a 6- to 8-fold increase in
PKC␣ and that this increase appears to be required for growth
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FIG. 7. Down-regulation of PKC decreases RAR binding to
RARE. B16 cells were treated with 10 M retinoic acid for 48 h in the
absence or presence of 10 M phorbol dibutyrate also for 48 h (PKC
down-regulation) or for the last hour of retinoid treatment (PKC activation). Cells were then harvested, and nuclear extracts were prepared
and incubated with a 32P-labeled DNA oligonucleotide corresponding to
a consensus DR-5 element. Complexes were separated on polyacrylamide gels, and bands were detected by autoradiography. Lane 1, DNA
probe only; lane 2, DNA plus nuclear extract. The open arrow indicates
the RAR䡠DNA complex; lane 3, DNA plus nuclear extract plus RAR
antibody. The closed arrow indicates the “super-shifted” complex. Lane
4, DNA plus nuclear extract from cells treated with phorbol dibutyrate
for 2 h; lane 5, DNA plus nuclear extract from cells treated with phorbol
dibutyrate for 24 h.

FIG. 6. Effect of PKC activation/down-regulation on RAR transcriptional transactivation activity. B16 cells were transfected
with an RARE-tk-luciferase reporter plasmid without (A) or with (B)
co-transfection of pSG5-RAR␣, ␤, or ␥ expression plasmids. 24 h posttransfection, cells were treated with 10 M retinoic acid alone or with 10
M phorbol dibutyrate (PKC down-regulation). For activation of PKC,
cells were treated with 10 M phorbol dibutyrate during the final 2 h of
incubation with retinoic acid. A, reporter gene activity in cells containing only the endogenous RAR. B, reporter gene activity in cells ectopically expressing RAR␣, ␤, or ␥.

arrest and differentiation (36). Because PKC has been reported
to phosphorylate RAR (29), we decided to investigate the potential interactions between PKC and RAR in our B16 melanoma model system.
Using transient transfection into B16 mouse melanoma cells
of a construct containing the gene for 6X-His-RAR␣, we found
that the encoded protein has multiple phosphorylated species
in agreement with previous published results (37). However, in
contrast to our expectations, activation or down-regulation of
the endogenous PKC, through the use of short and long term
phorbol dibutyrate treatment, did not change the phosphorylation status of the ectopically expressed RAR␣. This conclusion
is based on the observation that manipulation of PKC activity/
expression did not change the ratio of any of the phosphorylated species of RAR␣ nor the amount of 32Pi incorporated into
the RAR␣ when the data is corrected for the amount of RAR␣
protein present in the sample. Our finding differs from that of

FIG. 8. Down-regulation of PKC inhibits retinoic acid induction of RAR␤ mRNA. B16 cells were treated with 10 M phorbol
dibutyrate for 24 h alone, 10 M retinoic acid for 24 h alone, or with
phorbol dibutyrate for 24 h prior to the addition of retinoic acid for 24 h.
Cells were harvested, RNA was extracted, and the amount of RAR␤ was
determined by Northern blotting as described in the text.

Delmotte et al. (29), who showed that PKC␣ and ␥ were able to
phosphorylate RAR␣ in vitro on a single serine residue (Ser157). Furthermore, they have shown that this phosphorylation
site is at the dimerization interface and thus inhibits formation
of RAR䡠RXR heterodimer and transcriptional activity. We have
also found that PKC␣ was able to phosphorylate RAR␣ in vitro
(data not shown), however our present results suggest that this
phosphorylation most likely does not occur in vivo in B16
melanoma cells.
Although activation of PKC did not alter the phosphorylation
state of RAR␣, it did increase the amount of this protein. The
increase was not due to increased promoter activity of the
transfected plasmid, because the same promoter-driving ␤-galactosidase expression did not increase the expression of this
transfected gene when the cells were treated for 2 h with
phorbol dibutyrate. Although we did not measure RAR␣ mRNA
levels with or without addition of phorbol dibutyrate, it is
unlikely that changes in RNA level can account for the increase
in the amount of RAR␣ protein, because it was detected within
30 min of addition of phorbol dibutyrate to the cells. Indeed,
further investigation demonstrated that the increase could be
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correlated exactly with an increase in the half-life of the RAR␣
protein. It is clear that PKC enzyme activity is required for
short term phorbol dibutyrate treatment to increase RAR␣
protein. Both bisindolylmaleimide, a fairly specific inhibitor of
PKC, and dominant-negative mutants of PKC␣ that lack enzyme activity, blocked the increase in RAR␣ protein. Although
PKC␣ is the major isozyme expressed in B16 cells (31), we are
hesitant to claim that this PKC isotope is responsible for the
increase in RAR␣, because overexpression of dominant-negative PKC␣ could block maturation of other isozyme by sequestering phosphoinositide-dependent kinase and thus blocking
phosphorylation of the activation loop of the PKC enzyme (38).
Examination of the half-life of RAR␣ in control and treated
cells revealed that activation of PKC increased the half-life
from 4 to 8 h, whereas down-regulation of PKC decreased the
half-life to 3 h. This increase correlates quite well with the
increased steady-state level of RAR␣ in phorbol dibutyratetreated cells. Several recent studies have shown that the RARs
are degraded through the ubiquitin-proteasome pathway and
that binding of ligand by the receptor accelerates its degradation (39 – 41). Because RAR␣ did not appear to be directly
phosphorylated by PKC in vivo, we speculate that one of the
components of the ubiquitination-ligase system may be negatively regulated by PKC phosphorylation. Alternatively, PKCmediated phosphorylation of associated co-repressors may
block ligand-induced conformation change in the RAR␣, leading to stabilization of the protein. However, we consider this
mechanism unlikely in light of the increased AF-2 activity in
cells having activated PKC (see below).
In two studies PKC has been implicated in stabilizing protein half-life. Lee et al. (42) found that phosphorylation of EGF
receptors by PKC decreased their degradation by promoting
recycling back to the cell surface. Droms and Malkinson (43)
reported that PKC ␤II inhibited the proteasome-dependent
proteolysis of FUS nuclear proto-oncogene.
The increased amount of RAR protein in cells having activated PKC probably accounts for the increase in AF-2 activity
that we observed. This was found with ectopically expressed
RAR␣, ␤, and ␥ as well as with the endogenous RARs. However,
the large decrease in AF-2 activity found in PKC down-regulated cells cannot be explained by the change in the receptor
half-life from 4 to 3 h. We observed that the loss of PKC
resulted in a large decrease in receptor DNA binding. This loss
of receptor-DNA binding likely explains the drop in AF-2 activity.
One possibility is that down-regulation of PKC affects heterodimer formation of RAR with RXR. It has been reported that
RXR䡠RAR heterodimer formation is required for stable DNA
binding (14). RXR is also a phosphoprotein (44). However, at
present, it is not known whether it is phosphorylated by PKC in
vivo. Down-regulation of PKC also inhibited induction of RAR␤
mRNA by retinoic acid. This is consistent with a loss of AF-2
activity and DNA binding of RAR in PKC-down-regulated cells.
In summary, in B16 mouse melanoma cells, activation of
PKC increases the half-life of RAR␣, which correlates with enhanced AF-2 activity of all of the RAR. Down-regulation of PKC
leads to markedly decreased AF-2 activity of the RAR and inhibition of retinoic acid induction of one of its target genes, i.e.
RAR␤. Phorbol dibutyrate promotes the formation of skin tumors
when chronically applied to mouse skin (45, 46). We have shown
that chronic treatment of B16 mouse melanoma cells with phorbol dibutyrate inhibits the ability of retinoic acid to induce
growth arrest and differentiation in these cells (35, 47). Therefore, we hypothesize that phorbol dibutyrate may accomplish its
tumor promoting activity, at least in part, by down-regulating
PKC, which in turn blocks the ability of the RAR to transmit the
signal of retinoids to regulate growth and/or differentiation.
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